Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0004153 (atherosclerosis)
 77,401 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Colestipol hydrochloride, a polymeric, ion-exchange type, hypocholesterolemic agent, acting by sequestering bile acids, was labeled with carbon-14. The disposition of the labeled material was studied in the human, dog and rat. The extent of absorption from the gastrointestinal tract, as judged by urinary excretion of radioactivity, was very small and correlated well with the contents of water-soluble and dialyzable materials in the colestipol hydrochloride. Results were consistent with the dialyzable material in the drug being the absorbable species.
Atherosclerosis 1978 Jan
PMID:Preparation of [14C]colestipol hydrochloride and its disposition in the human, dog and rat. 62 28

To a group of 24 subjects with hypercholesterolaemia (hyperlipoproteinaemia type II) for a period of three months the non-absorbable resin Colestid was administered in order to reduce levels of atherogenic lipids and lipoproteins. The Colestid doses were graded from 5 g in the first month to 10-15 g during the third month. Reduction of cholesterol levels and the LDL fraction was significant already during the first month of treatment. The greatest reduction of LDL cholesterol was 25% and of total cholesterol 15%. A favourable effect was recorded also in HDL cholesterol which increased. The rise of triacylglycerols was not significant. Differences in the serum lipid response or their fractions did not depend on sex (15 women, 9 men), the clinical symptomatology (IHD) or family-history of atherosclerosis or concurrent administration of fibrates (Lipanthyl in 7 patients). In view of the small doses the symptomatology of side-effects was poor. Four patients, however, did not complete three months of treatment. With regard to the economical aspect of therapy and the favourable effect of small doses the authors draw attention to this experience which can be used as a basis also when using combinations with other preparations of antihypercholesterolemic therapy in those patients where an adequate reduction of cholesterol and its LDL fraction is not achieved.
 ...
PMID:[Small doses of the resin Colestid in the treatment of hyperlipoproteinemia]. 200 12

Young, male, SEA (Susceptible to Experimental Atherosclerosis) Japanese quail (Coturnix coturnix japonica) were fed an atherogenic diet consisting of yellow corn meal and soybean meal supplemented with 2% cholesterol and 1% cholic acid. A control group of ten animals was fed the atherogenic diet for eight weeks, and another group was fed the same diet containing 2% colestipol hydrochloride for the same length of time. At the end of the treatment period serum and arterial total cholesterols were measured and extent of macroscopic atherosclerotic lesions assessed. Colestipol hydrochloride treatment significantly reduced both serum and arterial total cholesterol levels by 50 and 59%, respectively. Grossly visible atherosclerosis was significantly reduced by 64%. These data further demonstrate that male SEA quail are an appropriate and relevant small animal model for examining the cardiovascular effects of bile acid sequestrants.
 ...
PMID:Anti-atherosclerotic activity of colestipol hydrochloride in SEA quail. 233 84

Male SEA (Susceptible to Experimental Atherosclerosis) quail were fed a semi-purified diet containing 0.5% cholesterol for a period of one week. Colestipol hydrochloride was mixed with the diet at levels of 0.5% and 1.0%. In control animals total serum cholesterol increased from a basal level of 241 mg/dl to 820 mg/dl after one week on the cholesterol supplemented diet. At 0.5% colestipol hydrochloride treated animals experienced a change in serum cholesterol from 223 mg/dl to 528 mg/dl after one week of cholesterol feeding. Colestipol hydrochloride at 1.0% in the diet completely prevented any increase in serum cholesterol in response to the hypercholesterolemic diet. Total serum cholesterols in this treatment group were 258 and 222 mg/dl initially and after the one week treatment, respectively. These data demonstrate that the bile acid sequestrant colestipol hydrochloride clearly prevents the hypercholesterolemia produced by feeding male SEA quail a cholesterol supplemented diet. Based on this activity cholesterol fed SEA quail may be a convenient and practical model for the preclinical evaluation of new cholesterol lowering drugs which act via a mechanism of bile acid sequestration.
 ...
PMID:Hypocholesterolemic activity of colestipol hydrochloride in SEA quail. 258 93

Twenty-two patients suffering from hyperlipidemia and receiving therapy consisting of a lipid-lowering diet and clofibrate (1 g X 2) were in addition given colestipol hydrochloride (5 g X 3) (Colestid, Upjohn) in a randomized, cross-over study for 2 periods of 6 weeks. Both the cholesterol and the triglyceride concentrations in very low density lipoproteins remained unchanged during the colestipol treatment. The cholesterol concentration in low density lipoproteins decreased by 23% (P < 0.001) and increased in high density lipoproteins by 4% (P < 0.01). In a second part of the project, the effects on the lipoprotein lipids of 15 g of colestipol divided into 1, 2 or 3 daily doses were studied when added to ongoing therapy with clofibrate (1 g X 2) and lipid-lowering diet. When the colespitol was divided into 2 or 3 daily doses, the effects were manifested equally but were less pronounced when 1 dose per day was given. In a third study, 14 patients who were treated with a combination of lipid-lowering diet, clofibrate (1 g X 2) and colestipol hydrochloride (15 g daily) were followed over a 2-year period, during which time the serum cholesterol and triglyceride concentrations were maintained at a reduced level. The fasting blood glucose and serum insulin concentrations were increased during colestipol treatment. Such treatment should therefore not be given to patients with impaired glucose tolerance.
Atherosclerosis 1980 Oct
PMID:The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies. 700 89